NCBP2 (NM_001042540) Human Tagged ORF Clone Lentiviral Particle
CAT#: RC221605L2V
- LentiORF®
Lenti ORF particles, NCBP2 (mGFP-tagged)-Human nuclear cap binding protein subunit 2, 20kDa (NCBP2), transcript variant 2, 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 8,360.00
货期*
详询
规格
Product images
经常一起买 (3)
Specifications
Product Data | |
Product Name | NCBP2 (NM_001042540) Human Tagged ORF Clone Lentiviral Particle |
Synonyms | CBC2; CBP20; NIP1; PIG55 |
Vector | pLenti-C-mGFP |
ACCN | NM_001042540 |
ORF Size | 309 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(RC221605).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_001042540.1, NP_001036005.1 |
RefSeq Size | 2016 bp |
RefSeq ORF | 312 bp |
Locus ID | 22916 |
Protein Families | Druggable Genome |
Protein Pathways | Spliceosome |
MW | 11.8 kDa |
Gene Summary | The product of this gene is a component of the nuclear cap-binding protein complex (CBC), which binds to the monomethylated 5' cap of nascent pre-mRNA in the nucleoplasm. The encoded protein has an RNP domain commonly found in RNA binding proteins, and contains the cap-binding activity. The CBC promotes pre-mRNA splicing, 3'-end processing, RNA nuclear export, and nonsense-mediated mRNA decay. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008] |
Documents
Product Manuals |
FAQs |
SDS |
Resources
You may also need
Customer
Reviews
Loading...